POT up +2.99% percent Today $POT High is at 36.88 and the

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
POT up +2.99% percent Today $POT High is at 36.88 and the Low 36.08 with current volume of 5,364,438.

Recent News posted below.

Potash Corp. of Saskatchewan Inc POT other info.
http://investorshangout.com/Potash-Corporatio...POT-52362/

POT Potash Corp. of Saskatchewan Inc Recent Headline News

Sinkhole found near Uralkali mine in Russia
Seeking Alpha - at Seeking Alpha - 1 hr 25 mins ago

AGU: 102.72 (+0.43), MOS: 47.84 (+1.07), POT: 36.46 (+1.06), IPI: 14.93 (+0.82)

Potash Corp. of Saskatchewan (POT) Stock Higher Today on Analyst Action
at The Street - 2 hrs ago
Potash Corp. of Saskatchewan (POT) stock is up this morning after the company was upgraded to 'outperform' from 'market perform' at Raymond James.
POT: 36.46 (+1.06)

Upgrade Alert for Potash (POT)
Comtex SmarTrend(R) - 2 hrs 26 mins ago
Potash (NYSE OT) was upgraded from Market Perform to Outperform at Raymond James today. The stock closed yesterday at $35.40 on volume of 12.9 million shares, above average daily volume of 4.6 million. Potash Corporation of Saskatchewan Inc. produces potash, phosphate, and nitrogen to the agricultural and industrial industries worldwide. The Company conducts operations in Canada, Chile, the United States, Brazil, and Trinidad.
POT: 36.46 (+1.06)

Potash Set to Possibly Pullback After Yesterday's Rally of 4.76%
Comtex SmarTrend(R) - Tue Nov 18, 3:54PM CST
Potash (NYSE OT) traded in a range yesterday that spanned from a low of $34.10 to a high of $35.83. Yesterday, the shares gained 4.8%, which took the trading range above the 3-day high of $33.97 on volume of 12.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
POT: 36.46 (+1.06)

Look for Shares of Potash to Potentially Pullback after Yesterday's 4.76% Rise
Comtex SmarTrend(R) - Tue Nov 18, 3:54PM CST
Potash (NYSE OT) traded in a range yesterday that spanned from a low of $34.10 to a high of $35.83. Yesterday, the shares gained 4.8%, which took the trading range above the 3-day high of $33.97 on volume of 12.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
POT: 36.46 (+1.06)

Potash Corp. of Saskatchewan (POT) Stock Soars After Uralkali Evacuates Mine
at The Street - Tue Nov 18, 1:19PM CST
Potash (POT) stock is up this afternoon as rival company Uralkali halted work at a potash mine in Russia.
POT: 36.46 (+1.06)

North American potash shares jump after Uralkali mine evacuation
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 10:25AM CST

AGU: 102.72 (+0.43), MOS: 47.84 (+1.07), POT: 36.46 (+1.06)

Potash Corporation - Attractive Dividend Hides An Overpriced Stock
Stock Market Sherpa - at Seeking Alpha - Thu Nov 13, 8:20AM CST

POT: 36.46 (+1.06)

Potash Corporation of Saskatchewan's board authorises USD0.35 per share dividend
M2 - Thu Nov 13, 5:40AM CST
The board of directors of Potash Corporation of Saskatchewan (TSX OT.TO), a crop nutrient company, on Wednesday declared a quarterly dividend of USD0.35 per share of the company's stock.
POT: 36.46 (+1.06)

Potash Corporation of Saskatchewan declares $0.35 dividend
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 4:33PM CST

POT: 36.46 (+1.06)

Potash Corporation of Saskatchewan Inc. Declares Quarterly Dividend
CNW Group - Wed Nov 12, 2:40PM CST
Listed: TSX, NYSE Symbol: POT
POT: 36.46 (+1.06), POT.TO: 41.36 (+1.35)

Capital Group boosts Potash Corp. stake above 10%
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:17PM CST

POT: 36.46 (+1.06)

Agrium (AGU) Unit to Acquire Equity Stake in CH Biotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 6:05PM CST
Agrium's (AGU) subsidiary Loveland Products has agreed to purchase an equity interest in CH Biotech.
CF: 272.13 (+2.44), AGU: 102.72 (+0.43), MOS: 47.84 (+1.07), POT: 36.46 (+1.06)

Potash Set to Possibly Pullback After Yesterday's Rally of 1.10%
Comtex SmarTrend(R) - Mon Nov 10, 4:43PM CST
Potash (NYSE OT) traded in a range yesterday that spanned from a low of $32.80 to a high of $33.20. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $33.15 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
POT: 36.46 (+1.06)

After Yesterday's Rally of 1.10% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Nov 10, 4:43PM CST
Potash (NYSE OT) traded in a range yesterday that spanned from a low of $32.80 to a high of $33.20. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $33.15 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
POT: 36.46 (+1.06)

Potash Earnings In Retrospect: Up 0.9% in the Last 18 Days (POT)
Comtex SmarTrend(R) - Mon Nov 10, 11:04AM CST
18 days ago, on October 23rd, 2014, Potash (NYSE OT) reported its earnings. Analysts, on average, expected earnings of $0.42 per share on sales of $1.5 billion. Potash actually reported earnings of $0.38 per share on sales of $1.6 billion, missing EPS estimates by $0.04 and beating revenue estimates by $113.0 million. Shares of Potash have climbed from $32.54 to $32.82, representing a gain of 0.9% since the company reported earnings 18 days ago.
POT: 36.46 (+1.06)

Is Potash Corp. of Saskatchewan Spending Enough to Remain the King of Fertilizer?
Tyler Crowe, The Motley Fool - Motley Fool - Sun Nov 09, 9:38AM CST
Any business out there, no matter how big its competitive advantage may be, can't simply sit back and watch the money come in. To maintain that competitive advantage -- and hopefully grow the business -- you have to be willing to spend money. Potash...
POT: 36.46 (+1.06)

CF Industries Misses Earnings and Revenue Estimates in Q3 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 11:20AM CST
CF Industries (CF) reported a roughly 44% fall in its profit in third-quarter 2014 to $130.9 million or $2.62 per share from $234.1 million or $4.07 per share a year ago, hurt by a double-digit fall in its sales.
CF: 272.13 (+2.44), AGU: 102.72 (+0.43), MOS: 47.83 (+1.06), POT: 36.46 (+1.06)

Agrium Misses Earnings Estimates in Q3, Hikes Dividend - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:30AM CST
Agrium Inc. (AGU) posted profit from continuing operations of $91 million or 63 cents per share in the third quarter of 2014, a rise of around 13.8% from $80 million or 54 cents per share registered a year ago.
CF: 272.13 (+2.44), AGU: 102.72 (+0.43), POT: 36.46 (+1.06)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 26

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Modexus Opens a $500 Million Buyback With Real Caveats

Updated Category News Views 68

A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...

Continue Reading
LRM Adds Two IND Studies Testing Injectable PDGF in Skin

Updated Category News Views 9

Under-eye medicine has a nasty habit of outrunning the evidence, which makes LRM's decision to put injectable rhPDGF-BB through more formal study worth watching. Lynch Regenerative Medicine has announced two FDA-accepted INDs for investigator-initiated clinical trials: one examining what the material does inside facial skin, the other testing it for infraorbital...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 39

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 35

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 182

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 159

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 148

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 32

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation into GoHealth, Inc. Sparks Investor Concerns

Updated Category News Views 354

GoHealth, Inc. Under Investigation for Alleged Securities Fraud Pomerantz LLP has initiated an investigation regarding potential claims involving investors of GoHealth, Inc. (NASDAQ: GOCO). This probe aims to determine whether the company and some of its executives have participated in misleading practices concerning their financial statements. The firm is reaching out to...

Continue Reading
Exploring the Features of the 2026 Toyota GR Corolla

Updated Category News Views 334

Unleashing the Adventure with the 2026 Toyota GR Corolla Get ready for an adventurous experience with the all-new 2026 Toyota GR Corolla. Engineered to perfection, this vehicle is equipped with the innovative GR-FOUR All-Wheel Drive System, making it a formidable companion whether you're racing on the track or maneuvering through rugged terrains. The GR Corolla is...

Continue Reading
Tandem Diabetes Care Boosts Sales Guidance After Q3 Success

Updated Category News Views 65

Tandem Diabetes Care Reports Impressive Q3 Financial Results Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading name in insulin delivery and diabetes management technology, has reported its financial accomplishments for the third quarter of 2024. Following an exceptional performance, the company has also increased its sales guidance for the upcoming fiscal year. Key...

Continue Reading
Green IT Services Growth: A Comprehensive Market Overview

Updated Category News Views 193

Green IT Services Market: A Dynamic Overview The evolution of technology is more than just a trend; it represents a paradigm shift towards sustainability. As organizations embrace digital transformation, the focus on Green IT services has rapidly gained importance. The latest analyses indicate that the Green IT Services market, valued at USD 18.8 billion in recent years,...

Continue Reading
Duke Energy's Response to Hurricane Helene's Aftermath

Updated Category News Views 558

Hurricane Helene Aftermath and Power Restoration Efforts Following the severe impact of Hurricane Helene, Duke Energy (NYSE: DUK) has made remarkable progress in restoring electrical services to over 2.16 million customers. Despite these extensive restoration efforts, around 334,000 customers are still without power, largely in Upstate South Carolina and the mountainous...

Continue Reading